-
公开(公告)号:US11801269B2
公开(公告)日:2023-10-31
申请号:US17852314
申请日:2022-06-28
IPC分类号: A61K35/37 , A61K35/24 , A61K35/74 , A61K35/741 , A61K9/00 , A61K35/742 , A61K9/16 , A61K47/08 , A61K47/26 , A61K45/06 , A61K35/00
CPC分类号: A61K35/37 , A61K9/0053 , A61K9/16 , A61K9/1617 , A61K9/1623 , A61K35/24 , A61K35/74 , A61K35/741 , A61K35/742 , A61K45/06 , A61K47/08 , A61K47/26 , A61K2035/11 , Y02A50/30 , A61K35/74 , A61K2300/00 , A61K35/24 , A61K2300/00
摘要: The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
-
公开(公告)号:US20220339203A1
公开(公告)日:2022-10-27
申请号:US17852314
申请日:2022-06-28
IPC分类号: A61K35/37 , A61K35/24 , A61K35/74 , A61K35/741 , A61K9/00 , A61K35/742 , A61K9/16 , A61K47/08 , A61K47/26 , A61K45/06
摘要: The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
-
公开(公告)号:US11202808B2
公开(公告)日:2021-12-21
申请号:US16235635
申请日:2018-12-28
申请人: Arizona Board of Regents on behalf of Arizona State University , Regents of the University of Minnesota , Finch Therapeutics Holdings LLC
发明人: James Adams , Rosa Krajmalnik-Brown , Dae-Wook Kang , Michael J. Sadowsky , Alexander Khoruts , Thomas J. Borody
摘要: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.
-
公开(公告)号:US10286012B2
公开(公告)日:2019-05-14
申请号:US15594319
申请日:2017-05-12
IPC分类号: A61K35/38 , A61K35/74 , A61K45/06 , A61K9/19 , A61K35/37 , A61K35/24 , A61K35/741 , A61K9/00 , A61K35/742 , A61K9/16 , A61K47/08 , A61K47/26 , A61K35/00
摘要: The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
-
公开(公告)号:US10251914B2
公开(公告)日:2019-04-09
申请号:US15626880
申请日:2017-06-19
IPC分类号: A61K35/74 , A61K35/24 , A61K35/37 , A61K35/741 , A61K9/00 , A61K35/742 , A61K9/16 , A61K47/08 , A61K47/26 , A61K45/06 , A61K35/00
摘要: The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
-
公开(公告)号:US20180000872A1
公开(公告)日:2018-01-04
申请号:US15258821
申请日:2016-09-07
IPC分类号: A61K35/741 , A61K9/16 , A61K9/19
CPC分类号: A61K35/741 , A61K9/145 , A61K9/1623 , A61K9/1682 , A61K9/19 , A61K9/28 , A61K9/4891 , A61K9/50 , A61K31/165 , A61K31/4164 , A61K31/43 , A61K31/435 , A61K31/496 , A61K31/498 , A61K31/65 , A61K31/7048 , A61K35/74 , A61P31/04
摘要: The present disclosure provides compositions and methods for treating Clostridium difficile infection (CDI) including primary and recurrent CDI. In particular, the compositions and methods described herein are capable of achieving a CDI clearance rate of at least 80% through a single oral dose of a pharmaceutical composition comprising a freeze-dried fecal microbiota preparation.
-
-
-
-
-